Zika in the Americas, year 2

What have we learned? What gaps remain? A report from the Global Virus Network

Matthew T. Aliota, Leda Bassit, Shelton Bradrick, Bryan Cox, Mariano Garcia-Blanco, Christina Gavegnano, Thomas C. Friedrich, Thaddeus G. Golos, Diane E. Griffin, Andrew D. Haddow, Esper G. Kallas, Uriel Kitron, Marc Lecuit, Diogo M. Magnani, Caroline Marrs, Natalia Mercer, Edward McSweegan, Lisa F.P. Ng, David H. O'Connor, Jorge E. Osorio & 11 others Guilherme S. Ribeiro, Michael Ricciardi, Shannan Rossi, George Saade, Raymond F. Schinazi, Geraldine O. Schott-Lerner, Chao Shan, Pei-Yong Shi, David I. Watkins, Nikos Vasilakis, Scott Weaver

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.

Original languageEnglish (US)
Pages (from-to)223-246
Number of pages24
JournalAntiviral Research
Volume144
DOIs
StatePublished - Aug 1 2017

Fingerprint

Viruses
Routine Diagnostic Tests
Antiviral Agents
Mosquito Control
Active Immunotherapy
Infectious Disease Transmission
Laboratory Animals
Pandemics
Disease Outbreaks
Vaccines
Public Health
Mothers
Research
Zika Virus Infection
Zika Virus
Therapeutics

Keywords

  • Antiviral therapy
  • Arbovirus
  • Congenital manifestations
  • Maternal-fetal transmission
  • Vaccines
  • Zika virus

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

Zika in the Americas, year 2 : What have we learned? What gaps remain? A report from the Global Virus Network. / Aliota, Matthew T.; Bassit, Leda; Bradrick, Shelton; Cox, Bryan; Garcia-Blanco, Mariano; Gavegnano, Christina; Friedrich, Thomas C.; Golos, Thaddeus G.; Griffin, Diane E.; Haddow, Andrew D.; Kallas, Esper G.; Kitron, Uriel; Lecuit, Marc; Magnani, Diogo M.; Marrs, Caroline; Mercer, Natalia; McSweegan, Edward; Ng, Lisa F.P.; O'Connor, David H.; Osorio, Jorge E.; Ribeiro, Guilherme S.; Ricciardi, Michael; Rossi, Shannan; Saade, George; Schinazi, Raymond F.; Schott-Lerner, Geraldine O.; Shan, Chao; Shi, Pei-Yong; Watkins, David I.; Vasilakis, Nikos; Weaver, Scott.

In: Antiviral Research, Vol. 144, 01.08.2017, p. 223-246.

Research output: Contribution to journalReview article

Aliota, MT, Bassit, L, Bradrick, S, Cox, B, Garcia-Blanco, M, Gavegnano, C, Friedrich, TC, Golos, TG, Griffin, DE, Haddow, AD, Kallas, EG, Kitron, U, Lecuit, M, Magnani, DM, Marrs, C, Mercer, N, McSweegan, E, Ng, LFP, O'Connor, DH, Osorio, JE, Ribeiro, GS, Ricciardi, M, Rossi, S, Saade, G, Schinazi, RF, Schott-Lerner, GO, Shan, C, Shi, P-Y, Watkins, DI, Vasilakis, N & Weaver, S 2017, 'Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network', Antiviral Research, vol. 144, pp. 223-246. https://doi.org/10.1016/j.antiviral.2017.06.001
Aliota, Matthew T. ; Bassit, Leda ; Bradrick, Shelton ; Cox, Bryan ; Garcia-Blanco, Mariano ; Gavegnano, Christina ; Friedrich, Thomas C. ; Golos, Thaddeus G. ; Griffin, Diane E. ; Haddow, Andrew D. ; Kallas, Esper G. ; Kitron, Uriel ; Lecuit, Marc ; Magnani, Diogo M. ; Marrs, Caroline ; Mercer, Natalia ; McSweegan, Edward ; Ng, Lisa F.P. ; O'Connor, David H. ; Osorio, Jorge E. ; Ribeiro, Guilherme S. ; Ricciardi, Michael ; Rossi, Shannan ; Saade, George ; Schinazi, Raymond F. ; Schott-Lerner, Geraldine O. ; Shan, Chao ; Shi, Pei-Yong ; Watkins, David I. ; Vasilakis, Nikos ; Weaver, Scott. / Zika in the Americas, year 2 : What have we learned? What gaps remain? A report from the Global Virus Network. In: Antiviral Research. 2017 ; Vol. 144. pp. 223-246.
@article{eb8fc7e2d4c54cb29283cabb5d48bc89,
title = "Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network",
abstract = "In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.",
keywords = "Antiviral therapy, Arbovirus, Congenital manifestations, Maternal-fetal transmission, Vaccines, Zika virus",
author = "Aliota, {Matthew T.} and Leda Bassit and Shelton Bradrick and Bryan Cox and Mariano Garcia-Blanco and Christina Gavegnano and Friedrich, {Thomas C.} and Golos, {Thaddeus G.} and Griffin, {Diane E.} and Haddow, {Andrew D.} and Kallas, {Esper G.} and Uriel Kitron and Marc Lecuit and Magnani, {Diogo M.} and Caroline Marrs and Natalia Mercer and Edward McSweegan and Ng, {Lisa F.P.} and O'Connor, {David H.} and Osorio, {Jorge E.} and Ribeiro, {Guilherme S.} and Michael Ricciardi and Shannan Rossi and George Saade and Schinazi, {Raymond F.} and Schott-Lerner, {Geraldine O.} and Chao Shan and Pei-Yong Shi and Watkins, {David I.} and Nikos Vasilakis and Scott Weaver",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.antiviral.2017.06.001",
language = "English (US)",
volume = "144",
pages = "223--246",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Zika in the Americas, year 2

T2 - What have we learned? What gaps remain? A report from the Global Virus Network

AU - Aliota, Matthew T.

AU - Bassit, Leda

AU - Bradrick, Shelton

AU - Cox, Bryan

AU - Garcia-Blanco, Mariano

AU - Gavegnano, Christina

AU - Friedrich, Thomas C.

AU - Golos, Thaddeus G.

AU - Griffin, Diane E.

AU - Haddow, Andrew D.

AU - Kallas, Esper G.

AU - Kitron, Uriel

AU - Lecuit, Marc

AU - Magnani, Diogo M.

AU - Marrs, Caroline

AU - Mercer, Natalia

AU - McSweegan, Edward

AU - Ng, Lisa F.P.

AU - O'Connor, David H.

AU - Osorio, Jorge E.

AU - Ribeiro, Guilherme S.

AU - Ricciardi, Michael

AU - Rossi, Shannan

AU - Saade, George

AU - Schinazi, Raymond F.

AU - Schott-Lerner, Geraldine O.

AU - Shan, Chao

AU - Shi, Pei-Yong

AU - Watkins, David I.

AU - Vasilakis, Nikos

AU - Weaver, Scott

PY - 2017/8/1

Y1 - 2017/8/1

N2 - In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.

AB - In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV-induced disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of ZIKV in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary ZIKV-induced disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.

KW - Antiviral therapy

KW - Arbovirus

KW - Congenital manifestations

KW - Maternal-fetal transmission

KW - Vaccines

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85021325699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021325699&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2017.06.001

DO - 10.1016/j.antiviral.2017.06.001

M3 - Review article

VL - 144

SP - 223

EP - 246

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -